Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection (cIAI)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00230971 |
|
Recruitment Status :
Completed
First Posted : October 3, 2005
Results First Posted : April 26, 2010
Last Update Posted : February 25, 2013
|
Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Information provided by (Responsible Party):
Wyeth is now a wholly owned subsidiary of Pfizer
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a study of the safety and efficacy of tigecycline to ceftriaxone sodium plus metronidazole in hospitalized subjects with cIAI. Subjects will be followed for efficacy through the test-of-cure assessment. Safety evaluations will occur through the treatment and post-treatment periods and continue through resolution or stability of the adverse event(s).
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Appendicitis Cholecystitis Diverticulitis Intra-Abdominal Abscess Intra-Abdominal Infection Peritonitis | Drug: tigecycline Drug: ceftriaxone plus metronidazole | Phase 4 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 473 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Multicenter, Open-Label, Randomized Comparative Study of Tigecycline vs Ceftriaxone Sodium Plus Metronidazole for the Treatment of Hospitalized Subjects With Complicated Intra-abdominal Infection |
| Study Start Date : | October 2005 |
| Actual Primary Completion Date : | September 2008 |
| Actual Study Completion Date : | September 2008 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
| Active Comparator: A |
Drug: tigecycline
every 12 hours IV (an initial dose of 100 mg followed by 50 mg every 12 hours) |
| Active Comparator: B |
Drug: ceftriaxone plus metronidazole
Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously. Test article should be administered for a minimum of 4 days and up to 14 days at the discretion of the investigator. |
Primary Outcome Measures :
- Number of Clinically Evaluable (CE) Patients With Clinical Response of Cure at the Test-of-Cure (TOC) Visit [ Time Frame: up to 6 weeks ]CE population were those who completed TOC assessment of cure or failure (but not indeterminate) or, in case of premature discontinuation due to lack of efficacy, had completed end of treatment assessment such that assessment of clinical response could be made. Clinical response was assigned by investigator per protocol-specified guidelines and defined as: test article and initial intervention (operative and/or radiologically controlled drainage procedure) resolved the intra-abdominal infection. TOC performed 10-28 days after last dose of study drug.
Secondary Outcome Measures :
- Number of Microbiologically Evaluable (ME) Patients With a Clinical Response of Cure at Test-of-Cure (TOC) Visit [ Time Frame: up to 6 weeks ]ME population were subjects who were clinically evaluable and had baseline culture with at least 1 identified isolate that was susceptible to study drug and comparator. The clinical response was assigned by the investigator according to the protocol-specified guidelines. A clinical response of cure was defined as: the test article and the initial intervention (operative and/or radiologically controlled drainage procedure) resolved the intra-abdominal infection.
- Number of Microbiologically Evaluable (ME) Patients by Microbiological Response at Test-of-Cure (TOC) Visit [ Time Frame: up to 6 weeks ]Microbiological response was assessed at patient level was the combined responses for all baseline isolates identified in intra-abdominal and blood cultures. Eradication=baseline isolate not recovered from primary infection site/blood; Presumed Eradication=No sample for culture, clinical response was cure; Persistence=baseline isolate recovered from primary infection site/blood; Presumed Persistence=No sample available for culture, clinical response was failure; Superinfection=culture from primary infection site with new isolate not identified at baseline, clinical response was failure.
- Number of Days of Inpatient Healthcare Resource Utilization on or Before Test-of-Cure [ Time Frame: up to 6 weeks ]Healthcare resource utilization assessment included days of overall inpatient hospitalization, days of primary inpatient hospitalization, days of Intensive Care Unit (ICU) treatment and days of non-ICU inpatient hospitalization
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Clinical diagnosis of complicated intra-abdominal infection that requires surgery within 24 hours.
- Fever plus other symptoms such as nausea, vomiting, abdominal pain.
Exclusion Criteria:
- Cancer
- Medicines that suppress the immune system
- Dialysis
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00230971
Locations
Show 68 study locations
Sponsors and Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
Investigators
| Study Director: | Medical Monitor | Wyeth is now a wholly owned subsidiary of Pfizer | |
| Principal Investigator: | Trial Manager | For Australia, China, Hong Kong, medinfo@wyeth.com | |
| Principal Investigator: | Trial Manager | For Taiwan, medinfo@wyeth.com | |
| Principal Investigator: | Trial Manager | For Denmark, Finland, MedInfoNord@wyeth.com | |
| Principal Investigator: | Trial Manager | For Germany, MedinfoDEU@wyeth.com | |
| Principal Investigator: | Trial Manager | For South Africa, ZAFinfo@wyeth.com | |
| Principal Investigator: | Trial Manager | For Italy, Greece, decresg@wyeth.com | |
| Principal Investigator: | Trial Manager | For UK, ukmedinfo@wyeth.com | |
| Principal Investigator: | Trial Manager | For Switzerland, med@wyeth.com | |
| Principal Investigator: | Trial Manager | For France, infomedfrance@wyeth.com | |
| Principal Investigator: | Trial Manager | For Spain, infomed@wyeth.com | |
| Principal Investigator: | Trial Manager | For Turkey, Erisc@wyeth.com |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Wyeth is now a wholly owned subsidiary of Pfizer |
| ClinicalTrials.gov Identifier: | NCT00230971 |
| Other Study ID Numbers: |
3074A1-315 |
| First Posted: | October 3, 2005 Key Record Dates |
| Results First Posted: | April 26, 2010 |
| Last Update Posted: | February 25, 2013 |
| Last Verified: | February 2013 |
Keywords provided by Wyeth is now a wholly owned subsidiary of Pfizer:
|
Intra-Abdominal Infections Abscess |
Additional relevant MeSH terms:
|
Infections Communicable Diseases Appendicitis Abscess Peritonitis Intraabdominal Infections Abdominal Abscess Cholecystitis Diverticulitis Disease Attributes Pathologic Processes Gastroenteritis Gastrointestinal Diseases Digestive System Diseases Cecal Diseases |
Intestinal Diseases Suppuration Inflammation Peritoneal Diseases Gallbladder Diseases Biliary Tract Diseases Diverticular Diseases Metronidazole Ceftriaxone Tigecycline Anti-Infective Agents Anti-Bacterial Agents Antiprotozoal Agents Antiparasitic Agents Protein Synthesis Inhibitors |